Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa

This publication has 15 references indexed in Scilit:

• The burden of malaria mortality among African children in the year 2000
  International Journal of Epidemiology, 2006
• Phase I Malaria Vaccine Trial with a Long Synthetic Peptide Derived from the Merozoite Surface Protein 3 Antigen
  Infection and Immunity, 2005
• A Malaria Vaccine That Elicits in Humans Antibodies Able to Kill Plasmodium falciparum
  PLoS Medicine, 2005
• Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children
  Vaccine, 2005
• Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
  Infection and Immunity, 2005
• Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720
  Vaccine, 2005
• A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults
  PLoS Medicine, 2004
• Association between Protection against Clinical Malaria and Antibodies to Merozoite Surface Antigens in an Area of Hyperendemicity in Myanmar: Complementarity between Responses to Merozoite Surface Protein 3 and the 220-Kilodalton Glutamate-Rich Protein
  Infection and Immunity, 2004
• Safety and Immunogenicity of DNA/Modified Vaccinia Virus Ankara Malaria Vaccination in African Adults
  The Journal of Infectious Diseases, 2003
• Merozoite Surface Protein 3 and Protection against Malaria inAotus nancymaiMonkeys
  The Journal of Infectious Diseases, 2002